KYLO-11
Intervention1 paper1 finding
C · W · M · H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
1 of 1 finding with company ties
- Human trial1
Outcomes
1Lipoprotein
downin humans1
1 study
Lipoprotein
downin humans1
KYLO-11 decreases lipoprotein in humans (-53% to -97%).
Human trialhealthy adults with elevated lipoprotein(a)subcutaneous injection9 to 600 mg48 weeksn = 70
Safety and lipoprotein(a)-lowering effects of Kylo-11, a non-canonical, long-duration small interfering RNA targeting lipoprotein(a): a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial · Lancet (London, England) · 28 Aug 2026